Literature DB >> 4814978

Effect of single oral doses of benzbromarone on serum and urinary uric acid.

A K Jain, J R Ryan, F G McMahon, R J Noveck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4814978     DOI: 10.1002/art.1780170207

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  8 in total

1.  [Action of benzbromarone on the renal excretion of allantoin in normouricemic and hyperuricemic humans (author's transl)].

Authors:  D Janzen; D P Mertz; E Scheiffele; O Kühnhold
Journal:  Klin Wochenschr       Date:  1977-11-01

2.  Rapid onset of uricosuria after oral administration of irtemazole, an uricosuric substance.

Authors:  U Gresser; U Kronawitter; O Adjan; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-10-17

3.  Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

Authors:  J N Colin; R Farinotti; G Fredj; M Tod; J P Clavel; E Vignon; F Dietlin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Uricosuric effect of irtemazole in healthy subjects.

Authors:  U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-10-02

5.  Pharmacokinetics and biotransformation of benzbromarone in man.

Authors:  H Ferber; H Vergin; G Hitzenberger
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 6.  Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

Review 7.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Uricosuric effect of different doses of irtemazole in normouricaemic subjects.

Authors:  U Gresser; I Kamilli; U Kronawitter; N Zöllner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.